(AOF) – Lumibird posted a net profit of 7.1 million euros, down 38%, for its 2023 financial year. The laser specialist published an Ebitda of 34.5 million euros, in improvement of 10% and a turnover of 203.6 million euros, an increase of 6.6%. The activity was marked by “a buoyant dynamic on all markets”, particularly in the defense/space segment which experienced growth of 30.9%, to 39.4 million euros. The medical division increased to 102.8 million euros, an increase of 5.5% over the period.
In a context of persistent inflationary pressures, the group’s gross margin rate is holding up in 2023, at 61.7% compared to 61.8% a year earlier.
In terms of prospects, Lumibird, after three years of strong investments, “is more than ever positioned to benefit from the growing trends in its markets”. In this context, the group, which will publish its revenue for the first quarter of 2024 on April 22, plans to maintain like-for-like growth above 8% and to continue improving its profitability.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.
Learn more about the Capital Goods sector
Rail investment plan
The French railway industry is in second place in Europe and third place worldwide. This industry displays a trade surplus, which generates more than 100,000 jobs in France. The announcement of the future plan for French rail transport provides in particular for the regeneration and modernization of the network, the average age of which is 30 years in our territory. This age is much higher than that of countries like Germany (17 years) and Switzerland (15 years). An annual investment increasing from 2.8 billion euros to nearly 4 billion euros should make it possible to maintain the entire network in good condition.